In the BioHarmony Drug Report Database
Latanoprostene bunod
Vyzulta (latanoprostene bunod) is a small molecule pharmaceutical. Latanoprostene bunod was first approved as Vyzulta on 2017-11-02. It is known to target prostaglandin F2-alpha receptor. Vyzulta’s patent is valid until 2025-10-03 (FDA).
Trade Name
|
Vyzulta |
|---|---|
Common Name
|
latanoprostene bunod |
ChEMBL ID
|
CHEMBL2364612 |
Indication
|
|
Drug Class
|
Nitrogen oxide (eg., nitrxyl and nitric oxide) donors; prostaglandins |
Image (chem structure or protein)